메뉴 건너뛰기




Volumn 46, Issue 3, 2015, Pages 332-337

Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis

Author keywords

Amikacin; Kanamycin; Limited sampling; Pharmacokinetic model; Pharmacokinetics; Tuberculosis

Indexed keywords

AMIKACIN; KANAMYCIN; TUBERCULOSTATIC AGENT;

EID: 84940451078     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.06.008     Document Type: Article
Times cited : (26)

References (32)
  • 3
    • 60749083864 scopus 로고    scopus 로고
    • Treatment outcomes among patients with multidrug-resistant tuberculosis: Systematic review and meta-analysis
    • E.W. Orenstein, S. Basu, N.S. Shah, J.R. Andrews, G.H. Friedland, A.P. Moll, and et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis Lancet Infect Dis 9 2009 153 161
    • (2009) Lancet Infect Dis , vol.9 , pp. 153-161
    • Orenstein, E.W.1    Basu, S.2    Shah, N.S.3    Andrews, J.R.4    Friedland, G.H.5    Moll, A.P.6
  • 5
    • 77951864345 scopus 로고    scopus 로고
    • Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections
    • P. Jureen, K. Angeby, E. Sturegard, E. Chryssanthou, C.G. Giske, J. Werngren, and et al. Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections J Clin Microbiol 48 2010 1853 1858
    • (2010) J Clin Microbiol , vol.48 , pp. 1853-1858
    • Jureen, P.1    Angeby, K.2    Sturegard, E.3    Chryssanthou, E.4    Giske, C.G.5    Werngren, J.6
  • 6
    • 0029018979 scopus 로고
    • A suggested approach to once-daily aminoglycoside dosing
    • E.J. Begg, M.L. Barclay, and S.B. Duffull A suggested approach to once-daily aminoglycoside dosing Br J Clin Pharmacol 39 1995 605 609
    • (1995) Br J Clin Pharmacol , vol.39 , pp. 605-609
    • Begg, E.J.1    Barclay, M.L.2    Duffull, S.B.3
  • 7
    • 0034861424 scopus 로고    scopus 로고
    • Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis
    • M. Zhu, W.J. Burman, G.S. Jaresko, S.E. Berning, R.W. Jelliffe, and C.A. Peloquin Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis Pharmacotherapy 21 2001 1037 1045
    • (2001) Pharmacotherapy , vol.21 , pp. 1037-1045
    • Zhu, M.1    Burman, W.J.2    Jaresko, G.S.3    Berning, S.E.4    Jelliffe, R.W.5    Peloquin, C.A.6
  • 8
    • 2942536119 scopus 로고    scopus 로고
    • Aminoglycoside toxicity: Daily versus thrice-weekly dosing for treatment of mycobacterial diseases
    • C.A. Peloquin, S.E. Berning, A.T. Nitta, P.M. Simone, M. Goble, G.A. Huitt, and et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases Clin Infect Dis 38 2004 1538 1544
    • (2004) Clin Infect Dis , vol.38 , pp. 1538-1544
    • Peloquin, C.A.1    Berning, S.E.2    Nitta, A.T.3    Simone, P.M.4    Goble, M.5    Huitt, G.A.6
  • 9
    • 0036636358 scopus 로고    scopus 로고
    • Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis
    • P. de Jager, and R. van Altena Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis Int J Tuberc Lung Dis 6 2002 622 627
    • (2002) Int J Tuberc Lung Dis , vol.6 , pp. 622-627
    • De Jager, P.1    Van Altena, R.2
  • 11
    • 33645346848 scopus 로고
    • New findings relate aminoglycoside ototoxicity to cumulative plasma or perilymph AUC
    • A. Beaubien New findings relate aminoglycoside ototoxicity to cumulative plasma or perilymph AUC Infect Dis Newsl 1992 11
    • (1992) Infect Dis Newsl , pp. 11
    • Beaubien, A.1
  • 12
    • 0032814522 scopus 로고    scopus 로고
    • Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity
    • M.J. Rybak, B.J. Abate, S.L. Kang, M.J. Ruffing, S.A. Lerner, and G.L. Drusano Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity Antimicrob Agents Chemother 43 1999 1549 1555
    • (1999) Antimicrob Agents Chemother , vol.43 , pp. 1549-1555
    • Rybak, M.J.1    Abate, B.J.2    Kang, S.L.3    Ruffing, M.J.4    Lerner, S.A.5    Drusano, G.L.6
  • 13
    • 0025881811 scopus 로고
    • Evidence that amikacin ototoxicity is related to total perilymph area under the concentration-time curve regardless of concentration
    • A.R. Beaubien, E. Ormsby, A. Bayne, K. Carrier, G. Crossfield, M. Downes, and et al. Evidence that amikacin ototoxicity is related to total perilymph area under the concentration-time curve regardless of concentration Antimicrob Agents Chemother 35 1991 1070 1074
    • (1991) Antimicrob Agents Chemother , vol.35 , pp. 1070-1074
    • Beaubien, A.R.1    Ormsby, E.2    Bayne, A.3    Carrier, K.4    Crossfield, G.5    Downes, M.6
  • 15
    • 84861043474 scopus 로고    scopus 로고
    • Dried blood spot analysis combined with limited sampling models can advance therapeutic drug monitoring of tuberculosis drugs
    • author reply 1766
    • J.W. Alffenaar Dried blood spot analysis combined with limited sampling models can advance therapeutic drug monitoring of tuberculosis drugs J Infect Dis 205 2012 1765 1766 [author reply 1766]
    • (2012) J Infect Dis , vol.205 , pp. 1765-1766
    • Alffenaar, J.W.1
  • 18
    • 84873048566 scopus 로고    scopus 로고
    • Benchmarking therapeutic drug monitoring software: A review of available computer tools
    • A. Fuchs, C. Csajka, Y. Thoma, T. Buclin, and N. Widmer Benchmarking therapeutic drug monitoring software: a review of available computer tools Clin Pharmacokinet 52 2013 9 22
    • (2013) Clin Pharmacokinet , vol.52 , pp. 9-22
    • Fuchs, A.1    Csajka, C.2    Thoma, Y.3    Buclin, T.4    Widmer, N.5
  • 19
    • 0033841587 scopus 로고    scopus 로고
    • Population pharmacokinetics of tobramycin in hospitalized patients receiving once-daily dosing regimen
    • D. Xuan, J.F. Lu, D.P. Nicolau, and C.H. Nightingale Population pharmacokinetics of tobramycin in hospitalized patients receiving once-daily dosing regimen Int J Antimicrob Agents 15 2000 185 191
    • (2000) Int J Antimicrob Agents , vol.15 , pp. 185-191
    • Xuan, D.1    Lu, J.F.2    Nicolau, D.P.3    Nightingale, C.H.4
  • 20
    • 33845353064 scopus 로고    scopus 로고
    • Performance of an iterative two-stage Bayesian technique for population pharmacokinetic analysis of rich data sets
    • J.H. Proost, and D.J. Eleveld Performance of an iterative two-stage Bayesian technique for population pharmacokinetic analysis of rich data sets Pharm Res 23 2006 2748 2759
    • (2006) Pharm Res , vol.23 , pp. 2748-2759
    • Proost, J.H.1    Eleveld, D.J.2
  • 21
    • 75649136552 scopus 로고    scopus 로고
    • Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis
    • J.W. Alffenaar, J.G. Kosterink, R. van Altena, T.S. van der Werf, D.R. Uges, and J.H. Proost Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis Ther Drug Monit 32 2010 97 101
    • (2010) Ther Drug Monit , vol.32 , pp. 97-101
    • Alffenaar, J.W.1    Kosterink, J.G.2    Van Altena, R.3    Van Der Werf, T.S.4    Uges, D.R.5    Proost, J.H.6
  • 23
    • 84870474781 scopus 로고    scopus 로고
    • Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies
    • Y. Wang, P.R. Jadhav, M. Lala, and J.V. Gobburu Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies J Clin Pharmacol 52 2012 1601 1606
    • (2012) J Clin Pharmacol , vol.52 , pp. 1601-1606
    • Wang, Y.1    Jadhav, P.R.2    Lala, M.3    Gobburu, J.V.4
  • 24
    • 0031955799 scopus 로고    scopus 로고
    • Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults
    • M. Tod, O. Lortholary, D. Seytre, R. Semaoun, B. Uzzan, L. Guillevin, and et al. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults Antimicrob Agents Chemother 42 1998 849 856
    • (1998) Antimicrob Agents Chemother , vol.42 , pp. 849-856
    • Tod, M.1    Lortholary, O.2    Seytre, D.3    Semaoun, R.4    Uzzan, B.5    Guillevin, L.6
  • 25
    • 79959733531 scopus 로고    scopus 로고
    • Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity
    • R. Galvez, C. Luengo, R. Cornejo, J. Kosche, C. Romero, E. Tobar, and et al. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity Int J Antimicrob Agents 38 2011 146 151
    • (2011) Int J Antimicrob Agents , vol.38 , pp. 146-151
    • Galvez, R.1    Luengo, C.2    Cornejo, R.3    Kosche, J.4    Romero, C.5    Tobar, E.6
  • 26
    • 0025355962 scopus 로고
    • Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity
    • R. Garraffo, H.B. Drugeon, P. Dellamonica, E. Bernard, and P. Lapalus Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity Antimicrob Agents Chemother 34 1990 614 621
    • (1990) Antimicrob Agents Chemother , vol.34 , pp. 614-621
    • Garraffo, R.1    Drugeon, H.B.2    Dellamonica, P.3    Bernard, E.4    Lapalus, P.5
  • 27
    • 6944234949 scopus 로고    scopus 로고
    • Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling
    • T. Gumbo, A. Louie, M.R. Deziel, L.M. Parsons, M. Salfinger, and G.L. Drusano Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling J Infect Dis 190 2004 1642 1651
    • (2004) J Infect Dis , vol.190 , pp. 1642-1651
    • Gumbo, T.1    Louie, A.2    Deziel, M.R.3    Parsons, L.M.4    Salfinger, M.5    Drusano, G.L.6
  • 28
    • 15944414245 scopus 로고    scopus 로고
    • Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia
    • M. Bernabeu-Wittel, C. Pichardo, A. García-Curiel, M.E. Pachón-Ibáñez, J. Ibáñez-Martínez, M.E. Jiménez-Mejías, and et al. Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia Clin Microbiol Infect 11 2005 319 325
    • (2005) Clin Microbiol Infect , vol.11 , pp. 319-325
    • Bernabeu-Wittel, M.1    Pichardo, C.2    García-Curiel, A.3    Pachón-Ibáñez, M.E.4    Ibáñez-Martínez, J.5    Jiménez-Mejías, M.E.6
  • 29
    • 2442708877 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections
    • E. Nuermberger, and J. Grosset Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections Eur J Clin Microbiol Infect Dis 23 2004 243 255
    • (2004) Eur J Clin Microbiol Infect Dis , vol.23 , pp. 243-255
    • Nuermberger, E.1    Grosset, J.2
  • 30
    • 84902185616 scopus 로고    scopus 로고
    • Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: A TBNET consensus statement
    • C. Lange, I. Abubakar, J.W. Alffenaar, G. Bothamley, J.A. Caminero, A.C. Carvalho, and et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement Eur Respir J 44 2014 23 63
    • (2014) Eur Respir J , vol.44 , pp. 23-63
    • Lange, C.1    Abubakar, I.2    Alffenaar, J.W.3    Bothamley, G.4    Caminero, J.A.5    Carvalho, A.C.6
  • 31
    • 84925234402 scopus 로고    scopus 로고
    • Therapeutic drug monitoring: How to improve drug dosage and patient safety in tuberculosis treatment
    • G. Sotgiu, J.W. Alffenaar, R. Centis, L. D'Ambrosio, A. Spanevello, A. Piana, and et al. Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment Int J Infect Dis 32 2015 101 104
    • (2015) Int J Infect Dis , vol.32 , pp. 101-104
    • Sotgiu, G.1    Alffenaar, J.W.2    Centis, R.3    D'Ambrosio, L.4    Spanevello, A.5    Piana, A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.